Skip to main content
SpringerLink
Log in

Association of the Pro12Ala gene polymorphism with treatment response to thiazolidinediones in patients with type 2 diabetes: a meta-analysis

  • Review Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

A Correction to this article was published on 13 June 2022

This article has been updated

Abstract

Background/purpose of the study

With the conflicting results on available studies regarding the association of the Pro12Ala polymorphism with the response of patients with type 2 diabetes mellitus (T2DM) to thiazolidinediones (TZDs), this meta-analysis was conducted to obtain more precise estimates.

Methods

Relevant studies were searched in PubMed and Google Scholar and were selected according to the set inclusion criteria. Data were extracted and analyzed using both Review Manager 5.4.1 and Meta-Essentials. Pooled mean difference (MD), standardized mean difference (SMD), and odds ratios (ORs) and their 95% confidence intervals were computed to measure the association of the polymorphism with TZD treatment response.

Results

Only four studies were included in this meta-analysis, with a sample size of 680. The pooled MD analysis results showed that FBG and HbA1c are significantly higher in the post-intervention group than in the pre-intervention group. No significant differences were noted between the genotypic groups (Pro12Pro vs. Pro12Ala and/or Ala12Ala). On the other hand, pooled OR analysis showed that T2DM that carry the PPARG gene variant are more likely to respond to TZD therapy.

Conclusion

Based on the results of this meta-analysis, our findings suggest that the presence of the PPARG gene variant is associated with the response of patients with T2DM to TZD therapy. However, further studies are still needed to verify our claims.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

References

  1. Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN. Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem. 2018;77:548–67.

    Article  CAS  Google Scholar 

  2. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002;18:S10–5.

    Article  CAS  Google Scholar 

  3. Jia C, Huan Y, Liu S, Hou S, Sun S, Li C, Liu Q, Jiang Q, Wang Y, Shen Z. Effect of chronic pioglitazone treatment on hepatic gene expression profile in obese C57BL/6J mice. Int J Mol Sci. 2015;16:12213–29.

    Article  CAS  Google Scholar 

  4. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl. 2001.

  5. Tyagi S, Gupta P, Saini A, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2:236–40.

    Article  CAS  Google Scholar 

  6. Alves MC, de Morais CC, Augusto EM, Abdalla DSP, Horst MA, Cominetti C. Polymorphisms in PPARG and APOE: relationships with lipid profile of adolescents with cardiovascular risk factors. Nutrire. 2017;42(1).

  7. Chan KHK, Niu T, Ma Y, You NCY, Song Y, Sobel EM, Hsu YH, Balasubramanian R, Qiao Y, Tinker L, Liu S. Common genetic variants in peroxisome proliferator-activated receptor-γ (PPARG) and type 2 diabetes risk among women’s health initiative postmenopausal women. J Clin Endocrinol Metab. 2013;98(3).

  8. Stryjecki C, Peralta-Romero J, Alyass A, Karam-Araujo R, Suarez F, Gomez-Zamudio J, Burguete-Garcia A, Cruz M, Meyre D. Association between PPAR-γ 32 Pro12Ala genotype and insulin resistance is modified by circulating lipids in Mexican children. Sci Rep. 2016;6.

  9. Johansson LE, Danielsson P, Norgren S, Marcus C, Ridderstråle M. Interaction between PPARG Pro12Ala and ADIPOQ G276T concerning cholesterol levels in childhood obesity. Int J Pediatr Obes. 2009;4(2):119–25.

    Article  Google Scholar 

  10. Hsiao TJ, Lin E. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma (PPARG) gene in relation to obesity and metabolic phenotypes in a Taiwanese population. Endocrine. 2015;48(3):786–93.

    Article  CAS  Google Scholar 

  11. Shanmuga Priya S, Sankaran R, Ramalingam S, Sairam T, Somasundaram L. Genotype phenotype correlation of genetic polymorphism of PPAR gamma gene and therapeutic response to pioglitazone in type 2 diabetes mellitus—a pilot study. J Clin Diagn Res. 2016;10(2):FC11–4.

    PubMed  Google Scholar 

  12. Trombetta M, Bonetti S, Boselli ML, Miccoli R, Trabetti E, Malerba G, Pignatti PF, Bonora E, Del Prato S, Bonadonna RC. PPARG2 Pro12Ala and ADAMTS9 rs4607103 as “insulin resistance loci” and “insulin secretion loci” in Italian individuals. the GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4. Acta Diabetol. 2013;50(3):401–8.

    Article  CAS  Google Scholar 

  13. Tellechea ML, Aranguren F, Pérez MS, Cerrone GE, Frechtel GD, Taverna MJ. Pro12Ala polymorphism of the peroxisome proliferator activated receptor-γ gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men. Circ J. 2009;73(11):2118–24.

    Article  CAS  Google Scholar 

  14. Watanabe RM, Black MH, Xiang AH, Allayee H, Lawrence JM, Buchanan TA. Genetics of gestational diabetes mellitus and type 2 diabetes. Diabetes Care. 2007;30(Supplement 2):S134–40.

    Article  CAS  Google Scholar 

  15. Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH. Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. Eur J Pharmacol. 2011;671(1–3):1–6.

    Article  CAS  Google Scholar 

  16. Hsieh MC, der Lin K, Tien KJ, te Tu S, Hsiao JY, Chang SJ, Lin SR, Shing SJ, Chen HC. Common polymorphisms of the peroxisome proliferator-activated receptor-γ (Pro12Ala) and peroxisome proliferator-activated receptor-γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metab Clin Exp. 2010;59(8):1139–44.

    Article  CAS  Google Scholar 

  17. Kang E, Park S, Kim H, Kim C, Ahn C, Cha B, Lim S, Nam C, Lee H. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Therap. 2005;78(2):202–8.

    Article  CAS  Google Scholar 

  18. Zhang R, Wang J, Yang R, Sun J, Chen R, Luo H, Liu D, Cai D. Effects of Pro12Ala polymorphism in peroxisome proliferator-activated receptor-γ2 gene on metabolic syndrome risk: a meta-analysis. Gene. 2014;553:90–7.

    Article  CAS  Google Scholar 

  19. Ramirez-Salazar M, Parez-Luque E, Fajardo-Araujo M, Garza SM, Malacara JM. Effect of the Pro12Ala polymorphism of the PPARγ32 gene on response to pioglitazone treatment in menopausal women. Menopause. 2008;15:1151–6.

    Article  Google Scholar 

  20. Blüher M, Lübben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care. 2003;26(3):825–31.

    Article  Google Scholar 

  21. Tiongco RE, Paragas NA, Dominguez MJ, Lasta SL, Pandac JK, Pineda-Cortel MR. ABO blood group antigens may be associated with increased susceptibility to schistosomiasis: a systematic review and meta-analysis. J Helminthol. 2018;11:1–10.

    Google Scholar 

  22. Pabalan N, Tiongco RE, Pandac JK, Paragas NA, Lasta S lo, Gallego N, Jarjanazi H, Pineda-Cortel MR. Association and biomarker potential of elevated serum adiponectin with nephropathy among type 1 and type 2 diabetics: a meta-analysis. PLoS ONE. 2018;13(12).

  23. Tiongco RE, Cabrera FJ, Clemente B, Flake CC, Salunga MA, Pineda-Cortel MR. G276T polymorphism in the ADIPOQ gene is associated with a reduced risk of polycystic ovarian syndrome: a meta-analysis of Asian population. Taiwan J Obstet Gynecol. 2019;58(3):409–16.

    Article  Google Scholar 

  24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

    CAS  PubMed  Google Scholar 

  25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  CAS  Google Scholar 

  26. Lau J, JPA I, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–6.

  27. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ : Br Med J. 2003;327(7414):557–60.

    Article  Google Scholar 

  28. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  Google Scholar 

  29. Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis. Res Synth Methods. 2017;8:537–53.

  30. Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator–activated receptor-γ2 gene variant. Diabetes Care. 2004;27(6):1365–8.

    Article  CAS  Google Scholar 

  31. Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications. Eur J Med Chem. 2019;166:502–13.

    Article  CAS  Google Scholar 

  32. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23(5):205–15.

    Article  CAS  Google Scholar 

  33. Arnold Sv., Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam CSP, Sperling LS, Kosiborod M. Understanding contemporary use of thiazolidinediones. Circulation: Heart Failure. 2019;12(6).

  34. Cresci S. PPAR genomics and pharmacogenomics: implications for cardiovascular disease. PPAR Res. 2008;2008:1–11.

    Article  Google Scholar 

  35. Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics. 2007;8(8):917–31.

    Article  CAS  Google Scholar 

  36. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 1995;270(22):12953–6.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, College of Allied Medical Professions, Angeles University Foundation, 2009, Angeles City, Philippines

    Johana Vallo, Roselle Arbas, Jan Erika Basilio, Christian Noel Miranda & Ma. Paulina Isabel Santos

  2. Department of Medical Technology, College of Allied Medical Professions, Angeles University Foundation, 2009, Angeles City, Philippines

    Ivy Cayabyab & Raphael Enrique Tiongco

  3. Dr. Mariano Que College of Pharmacy, De La Salle Medical and Health Sciences Institute, Dasmariñas, Cavite, Philippines

    Louie Fernand Legaspi

Authors
  1. Johana Vallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roselle Arbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Erika Basilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ivy Cayabyab
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Noel Miranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ma. Paulina Isabel Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Louie Fernand Legaspi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Raphael Enrique Tiongco
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors have contributed substantially to collecting and analyzing the data and in writing and critically revising the manuscript.

Corresponding author

Correspondence to Raphael Enrique Tiongco.

Ethics declarations

Ethics approval

This article does not contain any studies with human or animal subjects.

Consent to participate

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: In Table 3, last column 4th row under PA, it should be 0.0003**.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vallo, J., Arbas, R., Basilio, J.E. et al. Association of the Pro12Ala gene polymorphism with treatment response to thiazolidinediones in patients with type 2 diabetes: a meta-analysis. Int J Diabetes Dev Ctries 42, 412–419 (2022). https://doi.org/10.1007/s13410-022-01086-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-022-01086-z

Keywords

Search

Navigation